Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| Line 17: | Line 17: | ||
==Working Documents== | ==Working Documents== | ||
| + | *[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx| QIBA MSK Profile 2020-01-28:]] ''MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease'' | ||
==Statistical Reference Documents== | ==Statistical Reference Documents== | ||
Revision as of 21:17, 23 March 2020
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease